<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492128</url>
  </required_header>
  <id_info>
    <org_study_id>200706001</org_study_id>
    <nct_id>NCT00492128</nct_id>
  </id_info>
  <brief_title>Kanagawa Combination Anti-hypertensive Therapy (K-CAT)</brief_title>
  <official_title>Comparative Trial of Combination Therapy of ARB/Diuretic Versus ARB/CCB in Uncontrolled Hypertensive Patients With Monotherapy of ARB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yokohama City University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yokohama City University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect and safety of the antihypertensive
      combination therapies between losartan/amlodipine and fixed dose drug of
      losartan/hydrochlorothiazide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination therapy with multiple antihypertensive drugs is recommended in the patients
      who are uncontrolled with monotherapy. Diuretics increase the activities of
      renin-angiotensin-aldosterone system (RAS), and angiotensin receptor blockers (ARB) depress
      blood pressure potently in the state of increased RAS activities. Thus, the combination
      therapy with ARB and diuretics is expected to lower the blood pressure synergistically. This
      combination therapy is also expected to reduce the side effects of each drug. In this study,
      we will compare the effect and safety of the combination therapies between
      losartan/amlodipine and fixed dose drug of losartan/hydrochlorothiazide.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of systolic blood pressure</measure>
    <time_frame>three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The achievement rate of target blood pressure</measure>
    <time_frame>three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of diastolic blood pressure</measure>
    <time_frame>three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of blood pressure</measure>
    <time_frame>six months, nine months and one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The achievement rate of target blood pressure</measure>
    <time_frame>six months, nine months and one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">196</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Losartan/hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination drug with losartan 50mg and hydrochlorothiazide 12.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan/amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination therapy with losartan 50mg and amlodopine 5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan/amlodipine or losartan/hydrochlorothiazide</intervention_name>
    <description>Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.</description>
    <arm_group_label>Losartan/hydrochlorothiazide</arm_group_label>
    <arm_group_label>Losartan/amlodipine</arm_group_label>
    <other_name>Preminent (Hyzaar)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Under treatment of hypertension with ARB monotherapy for more than one month.

          -  systolic blood pressure more than 140mmHg and less than 160mmHg or diastolic blood
             pressure more than 90mmHg and less than 100mmHg in sitting position.

          -  In diabetic or CKD patients, systolic blood pressure more than 130mmHg and less than
             160mmHg or diastolic blood pressure more than 80mmHg and less than 100mmHg in sitting
             position.

        Exclusion Criteria:

          -  uncontrolled hypertension (diastolic blood pressure &gt;120mmHg)

          -  uncontrolled diabetes mellitus (HbA1c&gt;9.0%)

          -  Acute myocardial infarction, stroke and other cardiovascular events within six months

          -  The history of gout, or uric acid&gt;8.0mg/dl

          -  Serum creatinine&gt;2.0mg/dl

          -  sever liver dysfunction

          -  Bilateral renovascular stenosis

          -  secondary hypertension

          -  malignant hypertension

          -  uncontrolled arrhythmia

          -  pregnancy or possibility of pregnancy

          -  hypersensitivity to trial drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Satoshi Umemura, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Yokohama City University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yokohama City University Graduate School of Medicine</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2007</study_first_submitted>
  <study_first_submitted_qc>June 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <last_update_submitted>January 28, 2015</last_update_submitted>
  <last_update_submitted_qc>January 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yokohama City University Medical Center</investigator_affiliation>
    <investigator_full_name>Satoshi Umemura</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>angiotensin receptor blocker</keyword>
  <keyword>diuretic</keyword>
  <keyword>combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

